Lonza, SRU Biosystems | GenomeWeb

Lonza, SRU Biosystems

Lonza has developed new Amaxa Nucleofector kits for the transfection of primary mouse B cells, from single reactions up to 96-well transfections, the company announced this week.
Results of up to 74 percent transfection efficiency for stimulated mouse B cells and a viability of 59 percent for human hepatocytes 120 hours post nucleofection have been achieved, the company said.
New Amaxa Nucleofector kits are also available for the transfection of human hepatocytes and human chondrocytes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.